Article ID Journal Published Year Pages File Type
2122359 European Journal of Cancer 2012 13 Pages PDF
Abstract
Results support the favourable benefit-risk profile of pazopanib and suggest patients experiencing tumour response/stabilisation also may have better HRQoL compared to those without this response.
Keywords
Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Cancer Research
Preview
Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial
Authors
, , , , , , , , , ,